Disruptive Insider

Drug Discovery

3 articles

Editorial illustration for OpenAI Acquires Orchestra Bio to Bridge the Gap Between Drug Discovery and Development
Bio & Health Tech

OpenAI Acquires Orchestra Bio to Bridge the Gap Between Drug Discovery and Development

OpenAI has acquired Orchestra Bio, integrating its drug development coordination platform with OpenAI's Rosalind AI for life sciences. This move aims to accelerate drug discovery and development timelines by bridging scientific findings with operational execution.

Sofia Rodriguez·October 22, 2026
AI pioneer John Jumper, creator of AlphaFold, transitions from DeepMind to Anthropic, signaling a major shift in AI-driven drug discovery and research.
The Gaming Frontier

AI Pioneer John Jumper Departs DeepMind to Join Anthropic

On Friday, June 19, 2026, John Jumper, the Nobel laureate behind AlphaFold, announced his departure from Google DeepMind.

David Yazzie·June 21, 2026
Reid Hoffman, LinkedIn co-founder, transitions from Microsoft's corporate world to lead the AI drug discovery startup, Manus.
Founder Spotlight

Reid Hoffman exits Microsoft board for new AI startup Manus

Reid Hoffman, LinkedIn co-founder and prominent venture capitalist, is leaving Microsoft's board later this year.

Marco Giuliani·June 6, 2026